Bortecad 2.5 mg Injection

Injection de Bortecad 2.5 mg is a pharmaceutical product containing Bortezomib as its active ingredient. Bortezomib is a proteasome inhibitor used in the treatment of certain types of cancer, primarily multiple myeloma and mantle cell lymphoma. It works by inhibiting proteasomes, which are protein complexes within cells that break down unneeded or damaged proteins. By blocking proteasomes, Bortezomib leads to an accumulation of abnormal proteins in cancer cells, triggering cell death (apoptosis). This targeted action helps to slow or stop the growth of cancerous tumors.

Indications for Injection de Bortecad 2.5 mg include the treatment of multiple myeloma in patients who have received at least one prior therapy, and for the treatment of mantle cell lymphoma in patients who have received at least one prior therapy. The dosage and administration should be strictly determined by a qualified healthcare professional based on the patient’s condition and response to treatment. Common side effects may include fatigue, thrombocytopenia, diarrhea, constipation, peripheral neuropathy, and nausea. Patients should inform their doctor about any pre-existing medical conditions, especially nerve problems, heart conditions, or liver or kidney issues, before starting this medication. Storage instructions should be followed as per the manufacturer’s guidelines, typically involving refrigeration and protection from light.